Inclusion Criteria:

- Pts have confirmed diagnosis of GBM & radiographic evidence of recurrence following
prior therapy w bev + irinotecan

- Age >18 yrs

- Interval of >4 wks between prior surgical resection/1 week from stereotactic biopsy

- Interval of >12 wks from end of prior external beam radiation therapy (XRT) unless
there is new area of enhancement consistent w recurrent tumor outside of XRT
field,/there are progressive changes on MRI on >2 consecutive MRI scans >4wks apart,
/there is biopsy-proven tumor progression

- Interval of >4 wks from prior chemo / investigational agent unless pt has recovered
from all anticipated toxicities associated w that therapy.

- Eastern Cooperative Oncology Group (ECOG) 0-1

- Hematocrit >29percent, absolute neutrophil count (ANC)>1,000 cells/ml l, platelets >
100,000 cells/ml l

- Serum creatinine<1.5 mg/dl, serum glutamate oxaloacetate transaminase (SGOT) &
bilirubin<1.5 times upper limit of normal (ULN)

- Signed informed consent approved by Institutional Review Board (IRB) prior to pt
entry

- No evidence of hemorrhage on baseline MRI/CT scan other than those that are stable
gr1

- If sexually active, pts will take contraceptive measures for duration of treatments

Exclusion Criteria:

- Co-medication that may interfere w study results

- Active infection requiring intravenous antibiotics

- Progression to daily etoposide/progression to daily temo

- Gr3/greater toxicity related to prior bev therapy,/prior temozolomide/etoposide

- Requires therapeutic anti-coagulation with warfarin.

- Inability to comply w study and/or follow-up procedures

- Current, recent,/planned participation in experimental drug study other than
Genentech-sponsored bev cancer study

- Inadequately controlled hypertension

- Any prior history of hypertensive crisis/hypertensive encephalopathy

- New York Heart Association (NYHA) Gr II/greater congestive heart failure

- History of myocardial infarction (MI)/unstable angina within 6 mths prior to study
enrollment

- History of stroke/transient ischemic attack within 6 mths prior to study enrollment

- Significant vascular disease

- Symptomatic peripheral vascular disease

- Evidence of bleeding diathesis or coagulopathy

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to study enrollment or anticipation of need for major surgical procedure during
the course of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to study enrollment

- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to study enrollment

- Serious, non-healing wound, ulcer, or bone fracture

- Proteinuria at screening as demonstrated by either:

- urine protein:creatinine (UPC) ratio >1.0 at screening /

- Urine dipstick for proteinuria ≥ 2+

- Known hypersensitivity to any component of bevacizumab

- Pregnant or lactating. Use of effective means of contraception in subjects of
child-bearing potential